Nystatin is commonly prescribed as prophylaxis in children beyond the neonatal age.
Med Mycol
; 61(1)2022 Dec 29.
Article
em En
| MEDLINE
| ID: mdl-36610724
ABSTRACT
The indications for nystatin as prophylaxis or treatment are limited. In the PASOAP (Pediatric Antifungal Stewardship Optimizing Antifungal Prescription) study, high use of nystatin in hospitalized children beyond the neonatal age was observed. In this report, we present the data on nystatin use in infants and children ≥ 3 months who participated in the PASOAP study. Nystatin was prescribed mainly for prophylaxis. Congenital heart disease, cystic fibrosis, and chronic renal disease were the most commonly reported conditions in children receiving prophylactic nystatin. There is sparse evidence supporting the use of nystatin prophylaxis beyond neonates; trials in specific pediatric patient groups are required.
The topical antifungal nystatin has not many indications. Prophylaxis of invasive candidiasis in very low birth weight neonates is one of them. In our study, we found that nystatin prophylaxis was used frequently beyond this specific neonatal group. Stronger evidence justifying its use is required.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrose Cística
/
Doenças do Prematuro
Limite:
Animals
/
Humans
/
Newborn
Idioma:
En
Revista:
Med Mycol
Assunto da revista:
MEDICINA VETERINARIA
/
MICROBIOLOGIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Reino Unido